This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parad, R. B.
Right arrow Articles by Pier, G. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parad, R. B.
Right arrow Articles by Pier, G. B.

 Previous Article  |  Next Article 

Infection and Immunity, September 1999, p. 4744-4750, Vol. 67, No. 9
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Pulmonary Outcome in Cystic Fibrosis Is Influenced Primarily by Mucoid Pseudomonas aeruginosa Infection and Immune Status and Only Modestly by Genotype

Richard B. Parad,1,2 Craig J. Gerard,1 David Zurakowski,3 David P. Nichols,4 and Gerald B. Pier5,*

Division of Pulmonary Medicine, Ina Sue Perlmutter Cystic Fibrosis Research Laboratory,1 and Department of Biostatistics,3 Children's Hospital, and Channing Laboratory, Department of Medicine,5 and Joint Program in Neonatology,2 Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, and University of Chicago, Chicago, Illinois4

Received 3 May 1999/Returned for modification 21 June 1999/Accepted 29 June 1999

Whether allelic variants of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) independently contribute to pulmonary outcome in CF patients has not been resolved. We used both cross-sectional and mixed-model longitudinal analyses of data from CF patients that were at least 12 years old to determine the influence on pulmonary function (percent predicted forced expiratory volume [FEV1]) of the CFTR gene genotype, gender, mucoid Pseudomonas aeruginosa (MPA) infection status, presence of total opsonic antibody to MPA, and, separately, the opsonic antibody activity specific to the mucoid exopolysaccharide (MEP) surface antigen. Two different factors were independently associated with the lack of MPA infection: a high level of MEP-specific opsonic activity (MSOA), implicating an immunologically based mechanism of resistance to infection, and a lack of any type of opsonic antibody to MPA, indicative of no significant exposure or infection. This latter phenotype was found in a subset of CF patients who carried at least one uncommon CFTR gene allele suggestive of a genetic basis for resistance to infection in this group of older CF patients. For CF patients in whom both CFTR gene alleles were identified by screening for the 12 most common variants (75% of alleles), cross-sectional analysis showed that MPA infection was best correlated with lower percent predicted FEV1, while genotype (two versus one Delta F508 CFTR gene allele) and a low level of MSOA were associated with increased risk of infection. A mixed-model analysis of longitudinal spirometric measurements that considered multiple risk factors to derive regression equations was used to determine which clinical parameters had the greatest effect on the annual rate of decline in percent predicted FEV1. This analysis showed that the CFTR gene genotype only modestly modified the constant (y intercept) of the derived equations, while gender and MPA infection status had the largest effects on annual rates of decline in percent predicted FEV1. These results indicate that the CFTR genotype is usually not a primary determinant of pulmonary function in most CF patients, but gender and MPA infection status are. Infection status is potentially influenced by both immunologic (a high level of MSOA) and genetic factors, such as carriage of a CFTR gene allele that leads to a diagnosis of CF but still confers resistance to infection that is comparable to that of the wild-type CFTR gene.

* Corresponding author. Mailing address: Channing Laboratory, 181 Longwood Ave., Boston, MA 02115. Phone: (617) 525-2269. Fax: (617) 731-1541. E-mail: gpier{at}channing.harvard.edu.

Infection and Immunity, September 1999, p. 4744-4750, Vol. 67, No. 9
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Farrell, P. M., Collins, J., Broderick, L. S., Rock, M. J., Li, Z., Kosorok, M. R., Laxova, A., Gershan, W. M., Brody, A. S. (2009). Association between Mucoid Pseudomonas Infection and Bronchiectasis in Children with Cystic Fibrosis. Radiology 252: 534-543 [Abstract] [Full Text]  
  • Mulet, X., Macia, M. D., Mena, A., Juan, C., Perez, J. L., Oliver, A. (2009). Azithromycin in Pseudomonas aeruginosa Biofilms: Bactericidal Activity and Selection of nfxB Mutants. Antimicrob. Agents Chemother. 53: 1552-1560 [Abstract] [Full Text]  
  • Parks, Q. M., Young, R. L., Poch, K. R., Malcolm, K. C., Vasil, M. L., Nick, J. A. (2009). Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: human F-actin and DNA as targets for therapy. J Med Microbiol 58: 492-502 [Abstract] [Full Text]  
  • Kukavica-Ibrulj, I, Levesque, R C (2008). Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies. Lab Anim 42: 389-412 [Abstract] [Full Text]  
  • Reiniger, N., Lee, M. M., Coleman, F. T., Ray, C., Golan, D. E., Pier, G. B. (2007). Resistance to Pseudomonas aeruginosa Chronic Lung Infection Requires Cystic Fibrosis Transmembrane Conductance Regulator-Modulated Interleukin-1 (IL-1) Release and Signaling through the IL-1 Receptor. Infect. Immun. 75: 1598-1608 [Abstract] [Full Text]  
  • Stoltz, D. A., Ozer, E. A., Ng, C. J., Yu, J. M., Reddy, S. T., Lusis, A. J., Bourquard, N., Parsek, M. R., Zabner, J., Shih, D. M. (2007). Paraoxonase-2 deficiency enhances Pseudomonas aeruginosa quorum sensing in murine tracheal epithelia. Am. J. Physiol. Lung Cell. Mol. Physiol. 292: L852-L860 [Abstract] [Full Text]  
  • Ratjen, F., Rietschel, E., Kasel, D., Schwiertz, R., Starke, K., Beier, H., van Koningsbruggen, S., Grasemann, H. (2006). Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 57: 306-311 [Abstract] [Full Text]  
  • Starner, T. D., McCray, P. B. Jr. (2005). Pathogenesis of Early Lung Disease in Cystic Fibrosis: A Window of Opportunity To Eradicate Bacteria. ANN INTERN MED 143: 816-822 [Full Text]  
  • Walker, T. S., Tomlin, K. L., Worthen, G. S., Poch, K. R., Lieber, J. G., Saavedra, M. T., Fessler, M. B., Malcolm, K. C., Vasil, M. L., Nick, J. A. (2005). Enhanced Pseudomonas aeruginosa Biofilm Development Mediated by Human Neutrophils. Infect. Immun. 73: 3693-3701 [Abstract] [Full Text]  
  • Yarden, J, Radojkovic, D, De Boeck, K, Macek, M Jr, Zemkova, D, Vavrova, V, Vlietinck, R, Cassiman, J-J, Cuppens, H (2005). Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype. Thorax 60: 320-325 [Abstract] [Full Text]  
  • Li, Z., Kosorok, M. R., Farrell, P. M., Laxova, A., West, S. E. H., Green, C. G., Collins, J., Rock, M. J., Splaingard, M. L. (2005). Longitudinal Development of Mucoid Pseudomonas aeruginosa Infection and Lung Disease Progression in Children With Cystic Fibrosis. JAMA 293: 581-588 [Abstract] [Full Text]  
  • Mikerov, A. N., Umstead, T. M., Huang, W., Liu, W., Phelps, D. S., Floros, J. (2005). SP-A1 and SP-A2 variants differentially enhance association of Pseudomonas aeruginosa with rat alveolar macrophages. Am. J. Physiol. Lung Cell. Mol. Physiol. 288: L150-L158 [Abstract] [Full Text]  
  • Jain, M., Ramirez, D., Seshadri, R., Cullina, J. F., Powers, C. A., Schulert, G. S., Bar-Meir, M., Sullivan, C. L., McColley, S. A., Hauser, A. R. (2004). Type III Secretion Phenotypes of Pseudomonas aeruginosa Strains Change during Infection of Individuals with Cystic Fibrosis. J. Clin. Microbiol. 42: 5229-5237 [Abstract] [Full Text]  
  • Hadd, A. G., Laosinchai-Wolf, W., Novak, C. R., Badgett, M. R., Isgur, L. A., Goldrick, M., WalkerPeach, C. R. (2004). Microsphere Bead Arrays and Sequence Validation of 5/7/9T Genotypes for Multiplex Screening of Cystic Fibrosis Polymorphisms. J. Mol. Diagn. 6: 348-355 [Abstract] [Full Text]  
  • Pier, G. B., Boyer, D., Preston, M., Coleman, F. T., Llosa, N., Mueschenborn-Koglin, S., Theilacker, C., Goldenberg, H., Uchin, J., Priebe, G. P., Grout, M., Posner, M., Cavacini, L. (2004). Human Monoclonal Antibodies to Pseudomonas aeruginosa Alginate That Protect against Infection by Both Mucoid and Nonmucoid Strains. J. Immunol. 173: 5671-5678 [Abstract] [Full Text]  
  • Priebe, G. P., Dean, C. R., Zaidi, T., Meluleni, G. J., Coleman, F. T., Coutinho, Y. S., Noto, M. J., Urban, T. A., Pier, G. B., Goldberg, J. B. (2004). The galU Gene of Pseudomonas aeruginosa Is Required for Corneal Infection and Efficient Systemic Spread following Pneumonia but Not for Infection Confined to the Lung. Infect. Immun. 72: 4224-4232 [Abstract] [Full Text]  
  • Saiman, L., Siegel, J. (2004). Infection Control in Cystic Fibrosis. Clin. Microbiol. Rev. 17: 57-71 [Abstract] [Full Text]  
  • Steinkamp, G, Wiedemann, B (2002). Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax 57: 596-601 [Abstract] [Full Text]  
  • Lyczak, J. B., Cannon, C. L., Pier, G. B. (2002). Lung Infections Associated with Cystic Fibrosis. Clin. Microbiol. Rev. 15: 194-222 [Abstract] [Full Text]  
  • Saiman, L., Chen, Y., Gabriel, P. S., Knirsch, C. (2002). Synergistic Activities of Macrolide Antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans Isolated from Patients with Cystic Fibrosis. Antimicrob. Agents Chemother. 46: 1105-1107 [Abstract] [Full Text]  
  • Pier, G. B., Coleman, F., Grout, M., Franklin, M., Ohman, D. E. (2001). Role of Alginate O Acetylation in Resistance of Mucoid Pseudomonas aeruginosa to Opsonic Phagocytosis. Infect. Immun. 69: 1895-1901 [Abstract] [Full Text]  
  • Harder, J., Meyer-Hoffert, U., Teran, L. M., Schwichtenberg, L., Bartels, J., Maune, S., Schröder, J.-M. (2000). Mucoid Pseudomonas aeruginosa, TNF-alpha , and IL-1beta , but Not IL-6, Induce Human beta -Defensin-2 in Respiratory Epithelia. Am. J. Respir. Cell Mol. Bio. 22: 714-721 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»